KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Debt (2017 - 2020)

Historic Total Debt for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q1 2020 value amounting to $31.4 million.

  • Xenon Pharmaceuticals' Total Debt rose 10709.43% to $31.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was $31.4 million, marking a year-over-year increase of 10709.43%. This contributed to the annual value of $15.5 million for FY2019, which is N/A changed from last year.
  • Xenon Pharmaceuticals' Total Debt amounted to $31.4 million in Q1 2020, which was up 10709.43% from $15.5 million recorded in Q4 2019.
  • Xenon Pharmaceuticals' Total Debt's 5-year high stood at $31.4 million during Q1 2020, with a 5-year trough of $6.8 million in Q4 2017.
  • Over the past 4 years, Xenon Pharmaceuticals' median Total Debt value was $15.1 million (recorded in 2019), while the average stood at $14.8 million.
  • Within the past 5 years, the most significant YoY rise in Xenon Pharmaceuticals' Total Debt was 12017.16% (2019), while the steepest drop was 346.63% (2019).
  • Quarter analysis of 4 years shows Xenon Pharmaceuticals' Total Debt stood at $6.8 million in 2017, then skyrocketed by 118.78% to $14.9 million in 2018, then rose by 4.39% to $15.5 million in 2019, then skyrocketed by 101.76% to $31.4 million in 2020.
  • Its last three reported values are $31.4 million in Q1 2020, $15.5 million for Q4 2019, and $15.4 million during Q3 2019.